Hoe verhoudt HMDC.F's PS Ratio zich tot zijn concurrenten?

HMDC.F is een goede waarde op basis van zijn Price-To-Sales Ratio (3.2x) vergeleken met het gemiddelde van gelijken (8x).

Hoe verhoudt HMDC.F's PS Ratio zich tot andere bedrijven in de US Pharmaceuticals industrie?

HMDC.F is een goede waarde op basis van de Price-To-Sales -ratio ( 3.2 x) vergeleken met het US Pharmaceuticals -industriegemiddelde ( 2.9 x).

Wat is HMDC.F's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Sales Fair Ratio van { HMDC.F te berekenen voor waarderinganalyse.

Wat is de reële prijs van HMDC.F als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

HMDC.F ( $3.82 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( $13.46 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

HUTCHMED (China) (OTCPK:HMDC.F) - Aandelenkoers, Nieuws & Analyse

HMDC.F Overzicht aandelen

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. Meer informatie

HMDC.F fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	4/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 71.7% onder onze schatting van de reële waarde

De winst zal naar verwachting met 31.13% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

HUTCHMED (China) Limited Concurrenten

Wave Life Sciences

NasdaqGM:WVE

US$2.3b

Tarsus Pharmaceuticals

NasdaqGS:TARS

US$1.8b

Harmony Biosciences Holdings

NasdaqGM:HRMY

US$2.0b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$2.1b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor HUTCHMED (China)
Historische aandelenkoersen
Huidige aandelenkoers	UK£3.82
52 Week Hoogtepunt	UK£3.95
52 Week Laag	UK£2.05
Bèta	0.65
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	5.97%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	82.54%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	HMDC.F	US Pharmaceuticals	US Markt
7D	0%	4.2%	2.0%
1Y	6.0%	13.7%	32.4%

Rendement versus industrie: HMDC.F presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 13.7 % opleverde.

Rendement versus markt: HMDC.F presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 32.4 % opleverde.

Prijsvolatiliteit

Is HMDC.F's price volatile compared to industry and market?
HMDC.F volatility
HMDC.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: HMDC.F heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van HMDC.F in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2000	1,990	Wei-Guo Su	www.hutch-med.com

HUTCHMED (China) Limited Samenvatting

Hoe verhouden de winst en inkomsten van HUTCHMED (China) zich tot de beurswaarde?
HMDC.F fundamentele statistieken
Marktkapitalisatie	US$2.45b
Inkomsten(TTM)	-US$29.42m
Inkomsten(TTM)	US$757.24m

3.2x

P/S-verhouding

-83.3x

Koers/Winstverhouding

Is HMDC.F overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
HMDC.F resultatenrekening (TTM)
Inkomsten	US$757.24m
Kosten van inkomsten	US$731.89m
Brutowinst	US$25.34m
Overige uitgaven	US$54.77m
Inkomsten	-US$29.42m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

Feb 28, 2024

Winst per aandeel (EPS)	-0.034
Brutomarge	3.35%
Nettowinstmarge	-3.89%
Schuld/Eigen Vermogen Verhouding	5.0%

Hoe presteerde HMDC.F op de lange termijn?

Bekijk historische prestaties en vergelijking

HMDC.F Overzicht aandelen

Beloningen

Risicoanalyse

HUTCHMED (China) Limited Concurrenten

NasdaqGM:WVE

US$2.3b

NasdaqGS:TARS

US$1.8b

NasdaqGM:HRMY

US$2.0b

NasdaqGS:AMPH

US$2.1b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024

HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial

Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

HUTCHMED (China) Limited Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review

Recent updates

HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024

HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial

Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

HUTCHMED (China) Limited Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review

HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024

Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology

HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology

HUTCHMED (China) Limited Announces Executive Changes

HUTCHMED (China) Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED (China) Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED

HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee

HUTCHMED (China) Limited to Report Fiscal Year 2022 Results on Feb 28, 2023

HUTCHMED (China) Limited Announces Agreement with NHSA for Inclusion of ORPATHYS in the National Reimbursement Drug List in China

Hutchmed Completes Patient Enrollment of Eslim-01, A Phase Iii Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

HUTCHMED Initiates Rolling Submission of Nda to U.S. Fda for Fruquintinib for the Treatment of Refractory Colorectal Cancer

HUTCHMED (China) Limited Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

Hutchmed (China) Limited Initiates Phase 2/3 Trial of Fruquintinib

HUTCHMED (China) Limited Initiates Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited Announces Summary Results of the 691-Patient, Multi-Regional Clinical Trial

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

HUTCHMED (China) Limited Samenvatting

3.2x

-83.3x

Inkomsten en omzet